Opus Genetics Inc (IRD): Net earnings per share growth forecast for next year

Opus Genetics, Inc. (IRD) - corporate logo

Risks associated with rare pathologies and insurance complexities drive the historical trend of next year's EPS forecast, where 34.20 represents the current level of the metric. Opus Genetics Inc (IRD) aims for dominance in retinal treatment niches through genome correction. Meanwhile, GMP-certified laboratories ensure the production of pilot drug batches without equipment wear and tear.

IRD - Opus Bio Earnings growth forecast for next year over the range 10/25/2024 - 11/11/2026

Opus Genetics - analytical breakdowns and key metrics (IRD)

- price and consensus price forecast:
Price Chart Opus Genetics, Inc.|IRD - Average Forecast Price
- stock exchange capitalization data:
Market Value Opus Genetics|IRD - Full Business Value
- company book value details:
Accounting Value per Share Opus Genetics|IRD - Book Capitalization|Market Value to Book Value Ratio opusgtx.com|IRD - Company Total Asset Base
- business debt structure and liquidity details:
Total Debt to Equity Ratio Opus Genetics Inc|IRD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Opus Genetics, Inc.|IRD - Company Total Indebtedness|Debts to Book Capitalization Opus Genetics|IRD - Long-Term Debt|Company Short-Term Debt Opus Genetics|Quick Ratio opusgtx.com
- earnings and market ratios statistics:
IRD - Company Net Income|Future Profit Opus Genetics Inc|IRD - Market Price to Net Income Ratio|Forward P/E Multiple Opus Genetics, Inc.|IRD - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Opus Genetics|IRD - Operating profit before deduction of amortization|Earnings per share for the last twelve months Opus Genetics|IRD - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months opusgtx.com|IRD - Earnings per share increase in current year|Earnings growth forecast for next year Opus Genetics Inc
Analysis of all company metrics:Opus Genetics Inc, IRD
Brand item of Opus Genetics

Opus Genetics Inc (IRD) is investing significant resources into gene therapy R&D, making its financial stability dependent on future drug registrations. The current value of 34.20 reflects the analysts' consensus forecast for next year's profit changes, quantifying market expectations regarding the company's transition to monetization. By analyzing shifts in analyst expectations for EPS growth in year n+1, an investor can identify an overvaluation of the asset in the event of overly optimistic forecasts.

Competitors of Opus Genetics Inc

Net earnings per share growth forecast for next year Alcon Vision|Expected net earnings per share growth next year Bausch Health BLCO|Net earnings per share growth forecast for next year Glaukos Corporation (GKOS)|APLS: Net earnings per share change forecast for next year|Belite Bio Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Ocular Therapeutix Inc OCUL|HROW - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Viridian Corp VRDN|LENZ (LENZ Therapeutics, Inc.) - Expected earnings per share growth for next year|Oculis - Expected earnings per share trend next year|EYPT (EyePoint Pharmaceuticals, Inc.) - Earnings growth forecast for next year|KOD - Net earnings per one share growth forecast for next year|Earnings growth forecast for next year ALDX|KALA - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year OKYO Pharma OKYO|ADVM: Projected earnings per share growth rate for next year|Outlook Therapeutics, Inc. - Earnings growth forecast for next year|Expected net earnings per share growth next year Clearside Biomedical Inc|NBY (novabay.com) - Expected earnings per share growth for next year|KPRX: Projected earnings per share increase next year|ALIM (Alimera Sciences Inc) - Earnings growth forecast for next year|Eyenovia Corp (EYEN) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year GHSI|Expected earnings per share growth for next year Ocuphire Pharma Inc OCUP|Net earnings per share growth forecast for next year Opthea Ltd. OPT